ALTSTATION.IO

Kenvue Inc. (KVUE) Stock Analysis

By Nova Skye | AltStation.io | Updated October 15, 2026

Price

$17.96

Change

+1.15%

Market Cap

$34.51B

Avg Volume

22.1M

Company Overview

Kenvue Inc. is a consumer health giant operating within the Consumer Defensive sector and the Household and Personal Products industry. Headquartered in Summit, New Jersey, the company sells essential health and wellness products to everyday shoppers across North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. Its operations are divided into three core segments: Self Care, Skin Health and Beauty, and Essential Health. The product catalog covers everything from over-the-counter cold, allergy, and pain medications to oral care, baby care, and cosmetics. Key portfolio staples include household names like Tylenol, Motrin, Benadryl, Listerine, BAND-AID, Neutrogena, and Aveeno.

Kenvue operates as an established market leader across essential health categories rather than a niche player. Its competitive edge rests on an extensive lineup of legacy brands like Zyrtec, Nicorette, Imodium, Neosporin, and Johnson’s that drive predictable, repeat consumer purchases. The primary threat to this position is shelf-space pressure from private-label alternatives and lower-cost generic substitutes in both over-the-counter medicine and skincare. Defending core market share and brand loyalty against these low-cost options remains its central operational challenge. The scale across its three operating divisions gives it a defensive buffer that smaller rivals cannot match.

Incorporated in 2022, Kenvue is focused on managing its vast international footprint as a dedicated, standalone consumer health company. The business operates across seven major geographic regions while supporting modern offerings like digital diagnostics, telemedicine, vitamins, and supplements alongside traditional retail products. With heavy exposure to non-discretionary personal care and medicine, the company is built for steady cash generation and defensive resilience. It stands today as a mature consumer defensive pillar anchored by widespread retail distribution and non-cyclical consumer demand.

Key Financials

Market Cap

$34.51B

Revenue

$15.41B

EBITDA

$3.48B

Gross Margin

58.4%

Profit Margin

10.8%

Revenue Growth

3.0%

Total Cash

$1.11B

Total Debt

$8.61B

Free Cash Flow

$1.91B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

20.89

Forward P/E

14.49

Beta

0.45

52-Week High

$20.13

52-Week Low

$14.02

EPS

$0.86

50-Day Avg

$18.39

200-Day Avg

$18.05

Price/Book

3.27

Technical Analysis

KVUE trades at $17.96, 74% of the way from its $13.22 52-week low to its $19.67 high. The stock is 8.45% below that high and 36.25% above the low. Price sits 1.96% above the 20-day moving average of $17.66. Momentum is positive at 2.74% over five trading days and 2.21% over 20 trading days. Near-term support is $17.20, while $18.90 is the resistance level buyers need to clear.

Recent News and Developments

EU clears Kimberly-Clark’s Kenvue acquisition with conditions

The European Commission conditionally approved Kimberly-Clark’s acquisition of Kenvue on October 13. Kimberly-Clark offered to divest its tampon and other feminine-hygiene brands across the European Economic Area, including Kotex, to address competition concerns in Czechia, Estonia, and Slovakia. Source: Agence Europe

Bondholders back Kenvue note amendments

Kimberly-Clark received enough consents to amend all outstanding series of Kenvue notes as part of an exchange covering up to $7 billion in new Kimberly-Clark debt. Tender participation ranged from 73.64% to 98.37% across the seven series, and the amendments become operative only when the exchange offers settle. Source: Kimberly-Clark

KVUE jumps 3.86% to $18.70

Kenvue shares closed at $18.70 on October 15, up 3.86% for the session, after reaching an intraday high of $18.77. Trading volume was 9,668,001 shares. Source: StockScan

Market Sentiment and Analyst Recommendations

Bull Case

Kenvue produces $15.41 billion in revenue and has a $34.51 billion market cap, giving investors exposure to a large established consumer-health business. Revenue growth is positive at 3.0%. The stock’s 2.74% five-day momentum and position above the $17.66 moving average show that buyers currently have control. The $19.50 analyst target is above the $17.96 share price, while the high target reaches $23.00. The European Commission’s conditional approval removes one regulatory obstacle from Kimberly-Clark’s proposed acquisition, although required brand divestitures remain. Bondholder participation of 73.64% to 98.37% across seven note series also shows strong support for the financing amendments tied to the transaction.

Bear Case

A P/E of 20.89 is not cheap against revenue growth of just 3.0%. Kenvue carries $8.61 billion in debt against only $1.11 billion in cash, leaving limited balance-sheet flexibility. The stock is already 36.25% above its 52-week low and sits 74% of the way through its annual range, so part of the recovery is already priced in. Near-term resistance at $18.90 could stop the rally before shares reach the $19.50 analyst target. The European approval comes with required feminine-hygiene brand divestitures, showing that the acquisition still carries execution and regulatory conditions. A product-liability complaint filed on October 13 adds legal risk, and the supplied data gives no estimate of potential financial exposure.

What to Watch

The first catalyst is whether Kimberly-Clark’s acquisition progresses after the European Commission’s conditional approval on October 13. Investors should track whether the required divestitures, including Kotex across the European Economic Area, satisfy the stated competition concerns. The Kenvue note exchange is another key event because the amendments become operative only when the exchange offers settle. On the chart, $18.90 is the immediate test; a move above it would clear the 30-day high, while a drop below $17.20 would break near-term support. Watch whether the price remains above the $17.66 20-day moving average and whether five-day momentum stays positive after its recent 2.74% gain. Fundamentally, revenue growth needs to hold above the reported 3.0%, while any increase in the $8.61 billion debt load would weaken the case.

Analyst Consensus

NONE

Based on 12 analyst opinions

Low Target

$18.00

Mean Target

$19.50

High Target

$23.00

Earnings and Financial Data

Sector

Consumer Defensive

Industry

Household & Personal Products

Employees

21,780

Earnings & Dividends

Next Earnings

Nov 05, 2026

EPS (Trailing)

$0.86

Dividend Yield

473.0%

Payout Ratio

96.5%

Frequently Asked Questions

Is KVUE a good stock to buy?

KVUE has positive 3.0% revenue growth and trades above its $17.66 20-day moving average, but its P/E is 20.89 and debt is $8.61 billion. The takeaway is that the setup is constructive, but the valuation and debt leave little room for weak execution.

What is KVUE’s price target?

The analyst target is $19.50, with estimates ranging from $18.00 to $23.00. The takeaway is that the central target sits above the current $17.96 price, but the low target is nearly equal to it.

What are KVUE’s support and resistance levels?

Near-term support is $17.20, based on the 30-day low, and resistance is $18.90, based on the 30-day high. The takeaway is that these are the key levels for judging the stock’s next move.

How far is KVUE from its 52-week high?

KVUE is 8.45% below its $19.67 52-week high and 36.25% above its $13.22 low. The takeaway is that the stock has recovered strongly but has not returned to its yearly peak.

Does KVUE pay a dividend?

The supplied key and technical data do not include dividend information. The takeaway is that no dividend conclusion can be made from the provided data.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated October 15, 2026.